Iyshwarya Bhaskar Kalarani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iyshwarya Bhaskar Kalarani has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ramakrishnan Veerabathiran
Human Cytogenetics and Genomics Laboratory, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education
6 shared publications Shahil Ahamed Mansoor
Human Cytogenetics and Genomics Laboratory, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Tamilnadu, India
1 shared publicationVajagathali Mohammed
Human Cytogenetics and Genomics Laboratory, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Tamilnadu, India
1 shared publication- Vajagathali Mohammed
Medical Bionanotechnology, Faculty of Allied Health Sciences (FAHS), Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai 603103, TN, India
1 shared publication
Latest Publications
- Open Access
- 10 September 2025
- Published by Gdanski Uniwersytet Medyczny in European Journal of Translational and Clinical Medicine
- Vol. 8 (2) , 35-42
Meta-analysis of cytotoxic T lymphocyte antigen-4 (CTLA-4) genetic polymorphisms and Graves' disease
Meta-analysis of cytotoxic T lymphocyte antigen-4 (CTLA-4) genetic polymorphisms and Graves’ disease. Background: Graves’ disease (GD) is an autoimmune disorder specific to the thyroid, characterized by a complex etiology influenced by both genetic ...
- 10 September 2025
- Published by Gdanski Uniwersytet Medyczny in European Journal of Translational and Clinical Medicine
- Vol. 8 (2) , 35-42
Open AccessMeta-analysis of cytotoxic T lymphocyte antigen-4 (CTLA-4) genetic polymorphisms and Graves' disease
Meta-analysis of cytotoxic T lymphocyte antigen-4 (CTLA-4) genetic polymorphisms and Graves’ disease. Background: Graves’ disease (GD) is an autoimmune disorder specific to the thyroid, characterized by a complex etiology influenced by both genetic ...
- 1 August 2024
- Published by Springer Nature
- p. 313-329
The Role of Extracellular Vesicles in Aging: An Overview and Implications
- 1 August 2024
- Published by Springer Nature
- p. 313-329
The Role of Extracellular Vesicles in Aging: An Overview and Implications
- Open Access
- 16 November 2023
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 22 (5) , 134-144
A study to identify novel biomarkers associated with multiple myeloma
Background. multiple myeloma (mm) is a plasma cell cancer that affects white blood cells. plasma cells from the bone marrow grow abnormally, as a consequence of which patients have high amounts of monoclonal immunoglobulin in their blood and urine, poor renal function, and recurring infections due to this condition. osteolytic bone lesions and immunodeficiency also impact multiple myeloma patients’ longevity and quality of life. The disease accounts for 13 % of all hematological malignancies worldwide, making it the second most common blood cancer.Material and Methods. The studies investigating mm biomarkers from 2000 to 2021 are collected from various databases. “multiple myeloma”, “biomarkers”, “genetic markers”, “prognostic markers”, “epidemiology of multiple myeloma”, and “risk factors for multiple myeloma” are the key phrases utilized to gather the articles.Results. The scientific and medical research progressed into mm, and the number of cases increased over time and continues to rise, prompting researchers and clinicians to discover new consequences of the disease and new markers for prognosis, diagnosis, detection, and treatment of cancer in the earliest stages. Prognostic and predictive signs for illness recurrence and response to medication may be detected adequately by innovative potential biomarkers, which are more accurate than current approaches.Conclusion. treatment for multiple myeloma includes a variety of chemotherapeutic medicines, including immune modulators and proteasome inhibitors; however, most patients still experience recurrence after completing treatment. There have been numerous novel techniques for managing multiple myeloma, and this review summarises the most commonly used and the new ones that have appeared in the previously published articles.
- 16 November 2023
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 22 (5) , 134-144
Open AccessA study to identify novel biomarkers associated with multiple myeloma
Background. multiple myeloma (mm) is a plasma cell cancer that affects white blood cells. plasma cells from the bone marrow grow abnormally, as a consequence of which patients have high amounts of monoclonal immunoglobulin in their blood and urine, poor renal function, and recurring infections due to this condition. osteolytic bone lesions and immunodeficiency also impact multiple myeloma patients’ longevity and quality of life. The disease accounts for 13 % of all hematological malignancies worldwide, making it the second most common blood cancer.Material and Methods. The studies investigating mm biomarkers from 2000 to 2021 are collected from various databases. “multiple myeloma”, “biomarkers”, “genetic markers”, “prognostic markers”, “epidemiology of multiple myeloma”, and “risk factors for multiple myeloma” are the key phrases utilized to gather the articles.Results. The scientific and medical research progressed into mm, and the number of cases increased over time and continues to rise, prompting researchers and clinicians to discover new consequences of the disease and new markers for prognosis, diagnosis, detection, and treatment of cancer in the earliest stages. Prognostic and predictive signs for illness recurrence and response to medication may be detected adequately by innovative potential biomarkers, which are more accurate than current approaches.Conclusion. treatment for multiple myeloma includes a variety of chemotherapeutic medicines, including immune modulators and proteasome inhibitors; however, most patients still experience recurrence after completing treatment. There have been numerous novel techniques for managing multiple myeloma, and this review summarises the most commonly used and the new ones that have appeared in the previously published articles.
- Open Access
- 31 December 2022
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 27 (4) , 256-264
Impact of iodine intake on the pathogenesis of autoimmune thyroid disease in children and adults
Thyroid hormone (TH) regulates the body's metabolism and iodine, a vital trace mineral, is vital for TH synthesis. As a TH biosynthesis catalyst, iodine has a substantial role in our health. When there is a modest iodine deficit, the thyroid gland grows autonomously, resulting in thyrotoxicosis. Those who consume excessive iodine risk developing hypothyroidism and thyroid autoimmunity. A transient hyperthyroid condition may rapidly increase iodine consumption. Iodine deficiency is common across the globe, and provision of supplementary iodine, in forms such as iodized salt or vegetable oil, has many benefits. Vegetarians, for instance, may not consume adequate amounts of iodine in some countries with high iodine content. Reduced dietary iodine intakes may be a consequence of efforts to reduce salt intakes to prevent hypertension. In addition, iodine consumption is decreasing in many countries, even among those where endemic goiter has previously been eradicated, leading to the re-emergence of iodine-deficiency-related disorders such as goiter. This review will discuss how iodine can contribute to the development of thyroid disease.
- 31 December 2022
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 27 (4) , 256-264
Open AccessImpact of iodine intake on the pathogenesis of autoimmune thyroid disease in children and adults
Thyroid hormone (TH) regulates the body's metabolism and iodine, a vital trace mineral, is vital for TH synthesis. As a TH biosynthesis catalyst, iodine has a substantial role in our health. When there is a modest iodine deficit, the thyroid gland grows autonomously, resulting in thyrotoxicosis. Those who consume excessive iodine risk developing hypothyroidism and thyroid autoimmunity. A transient hyperthyroid condition may rapidly increase iodine consumption. Iodine deficiency is common across the globe, and provision of supplementary iodine, in forms such as iodized salt or vegetable oil, has many benefits. Vegetarians, for instance, may not consume adequate amounts of iodine in some countries with high iodine content. Reduced dietary iodine intakes may be a consequence of efforts to reduce salt intakes to prevent hypertension. In addition, iodine consumption is decreasing in many countries, even among those where endemic goiter has previously been eradicated, leading to the re-emergence of iodine-deficiency-related disorders such as goiter. This review will discuss how iodine can contribute to the development of thyroid disease.
- Open Access
- 7 December 2022
- Published by Gdanski Uniwersytet Medyczny in European Journal of Translational and Clinical Medicine
- Vol. 5 (2) , 57-66
The role of biomarkers in early prediction and molecular mechanisms of preeclampsia
Preeclampsia (PE) is defined as new onset hypertension after 20 weeks of gestation with evidence of maternal organ or uteroplacental dysfunction or proteinuria. PE is a leading cause of maternal death, with about 55000 deaths worldwide each year. Toxic substances that damage the maternal vascular endothelium induce PE, resulting in liver and kidney malfunction. It is crucial for obstetricians to identify as early as possible the patients who are at risk for PE. Polycystic ovarian disease, sleeping disorders, urinary infections, periodontal disease, smoking, lifestyle and familial history of PE are the major risk factors involved in this disease. VEGF, sFlt1, sENG, PAPP-A, inhibin A and activin A proteins, fetal hemoglobin, heat shock protein and placental protein have been helpful in predicting or diagnosing PE and in understanding its pathogenesis. In addition, a better understanding of PE pathogenesis would aid in identifying the most effective treatments that do not impair the fetus’ prognosis. The aim of our study is a review of the pathophysiology and biomarkers, such as pro- and anti-angiogenic substances, that may be useful in the detection of PE in the future.
- 7 December 2022
- Published by Gdanski Uniwersytet Medyczny in European Journal of Translational and Clinical Medicine
- Vol. 5 (2) , 57-66
Open AccessThe role of biomarkers in early prediction and molecular mechanisms of preeclampsia
Preeclampsia (PE) is defined as new onset hypertension after 20 weeks of gestation with evidence of maternal organ or uteroplacental dysfunction or proteinuria. PE is a leading cause of maternal death, with about 55000 deaths worldwide each year. Toxic substances that damage the maternal vascular endothelium induce PE, resulting in liver and kidney malfunction. It is crucial for obstetricians to identify as early as possible the patients who are at risk for PE. Polycystic ovarian disease, sleeping disorders, urinary infections, periodontal disease, smoking, lifestyle and familial history of PE are the major risk factors involved in this disease. VEGF, sFlt1, sENG, PAPP-A, inhibin A and activin A proteins, fetal hemoglobin, heat shock protein and placental protein have been helpful in predicting or diagnosing PE and in understanding its pathogenesis. In addition, a better understanding of PE pathogenesis would aid in identifying the most effective treatments that do not impair the fetus’ prognosis. The aim of our study is a review of the pathophysiology and biomarkers, such as pro- and anti-angiogenic substances, that may be useful in the detection of PE in the future.
- Open Access
- 26 April 2022
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
- Vol. 10 (1) , 1-11
Gene-editing of CCR5 for the Treatment of HIV: A Novel Therapeutic Approach
- 26 April 2022
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
- Vol. 10 (1) , 1-11
Open AccessGene-editing of CCR5 for the Treatment of HIV: A Novel Therapeutic Approach